Free Trial

Oncolytics Biotech (ONCY) Earnings Date, Estimates & Call Transcripts

$1.02
-0.01 (-0.97%)
(As of 06/14/2024 ET)

Earnings Summary

Upcoming
Earnings Date
Aug. 12Estimated
Actual EPS
(May. 9)
-$0.07 Beat By $0.02
Consensus EPS
(May. 9)
-$0.09
Skip Charts & View Estimated and Actual Earnings Data

ONCY Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

ONCY Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Oncolytics Biotech Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q4 20241($0.04)($0.04)($0.04)
20241($0.04)($0.04)($0.04)
Q1 20252($0.09)($0.07)($0.08)
Q2 20251($0.07)($0.07)($0.07)
Q3 20251($0.08)($0.08)($0.08)
Q4 20251($0.07)($0.07)($0.07)
FY 20255($0.31)($0.29)($0.30)

ONCY Earnings Date and Information

Oncolytics Biotech last announced its earnings data on May 9th, 2024. The reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.09) by $0.02. Oncolytics Biotech has generated ($0.30) earnings per share over the last year (($0.30) diluted earnings per share). Earnings for Oncolytics Biotech are expected to decrease in the coming year, from ($0.29) to ($0.32) per share. Oncolytics Biotech has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, August 12th, 2024 based off prior year's report dates.

Oncolytics Biotech Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
8/12/2024
(Estimated)
------- 
5/9/2024Q1 2024($0.09)($0.07)+$0.02($0.07)--
3/7/2024Q4 2023($0.11)($0.04)+$0.07($0.04)--
11/3/2023Q3 2023($0.07)($0.10)($0.03)($0.10)--    
8/14/2023Q2 2023($0.09)($0.09)-($0.09)--    
5/5/2023Q1 2023($0.07)($0.07)-($0.07)--
3/3/2023Q4 2022($0.05)($0.10)($0.05)($0.10)--
11/7/2022Q3 2022($0.09)($0.06)+$0.03($0.06)--
8/11/2022Q2 2022($0.09)($0.07)+$0.02($0.07)--
5/5/2022Q1 2022($0.13)($0.09)+$0.04($0.09)--
3/3/2022Q4 2021($0.14)($0.11)+$0.03($0.11)--
11/5/2021Q3 2021($0.11)($0.07)+$0.04($0.07)--    
8/6/2021Q2 2021($0.10)($0.11)($0.01)($0.11)--
5/7/2021Q1 2021($0.17)($0.10)+$0.07($0.10)--
3/5/2021Q4 2020($0.13)($0.16)($0.03)($0.16)--
11/16/2020Q3 2020($0.10)($0.16)($0.06)($0.12)--  
8/4/2020Q2 2020($0.15)($0.12)+$0.03($0.12)--
5/8/2020Q1 2020($0.14)($0.15)($0.01)($0.27)--
3/5/2020Q4 2019($0.11)($0.19)($0.08)$0.16--
11/12/2019Q3 2019($0.19)($0.12)+$0.07($0.12)--
8/13/2019Q2 2019-($0.19)($0.19)($0.19)--

Oncolytics Biotech Earnings - Frequently Asked Questions

When is Oncolytics Biotech's earnings date?

Oncolytics Biotech has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, August 12th, 2024 based off last year's report dates. Learn more on ONCY's earnings history.

Did Oncolytics Biotech beat their earnings estimates last quarter?

In the previous quarter, Oncolytics Biotech (NASDAQ:ONCY) reported ($0.07) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.09) by $0.02. Learn more on analysts' earnings estimate vs. ONCY's actual earnings.

How much profit does Oncolytics Biotech generate each year?

Oncolytics Biotech (NASDAQ:ONCY) has a recorded net income of -$20.56 million. ONCY has generated -$0.30 earnings per share over the last four quarters.

What is Oncolytics Biotech's EPS forecast for next year?

Oncolytics Biotech's earnings are expected to decrease from ($0.29) per share to ($0.32) per share in the next year.


More Earnings Resources from MarketBeat

This page (NASDAQ:ONCY) was last updated on 6/15/2024 by MarketBeat.com Staff

From Our Partners